Aurobindo Pharma Limited has received final approval from the US Food & Drug Administration (US FDA) to manufacture and market didanosine delayed release (Enteric-Coated) capsules 125mg, 200mg, 250mg and 400mg.

Didanosine delayed release capsules is the generic version of Bristol Myer Squibb's Videx EC (didanosine) Delayed-release capsules, 125mg, 200mg, 250mg and 400mg and is indicated for the treatment of HIV-1 infections in adults. According to Aurobindo's press release this is the company's 78th approval from US FDA.